Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial

or

Watchlist | Portfolio | Dashboard

quotes
- Price Overview
- Performance Report
charts
- Interactive Chart
- Snapshot Chart
technicals
company
analysts
- Earnings Estimates
- Analyst Ratings
financials

Coya Therapeutics Inc (COYA)

Coya Therapeutics Inc (COYA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

News & Headlines for [[ item.sessionDateDisplayLong ]]

Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023 Business Wire - Fri Mar 31, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, today announced...

Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results Business Wire - Wed Mar 29, 2023

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells...

Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer Business Wire - Mon Mar 27, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET Business Wire - Thu Mar 23, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics...

Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET Business Wire - Tue Mar 21, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) Business Wire - Tue Mar 21, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases Business Wire - Mon Mar 20, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET Business Wire - Thu Mar 9, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. Business Wire - Mon Feb 27, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Coya Therapeutics, Inc. Announces Expansion of Exclusive Worldwide Licensing Agreement with ARScience Biotherapeutics, Inc. for Development and Commercialization of COYA 301, Coya’s Low-Dose Interleukin 2 (IL-2) Product Candidate Business Wire - Wed Feb 15, 2023

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including...

Want to use this as
your default charts setting?

Save this setup as a Chart Templates

Switch the Market flag

for targeted data from your country of choice.

Open the menu and switch the
Market flag for targeted data from your country of choice.

Want Streaming Chart Updates?

Switch your Site Preferences
to use Interactive Charts

Need More Chart Options?

Right-click on the chart to open the Interactive Chart menu.

Use your up/down arrows to move through the symbols.

Free Barchart Webinar